Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Decipher the device reference

This article was originally published in The Gray Sheet

Executive Summary

CDRH Office of Science & Engineering Laboratories Director Larry Kessler stresses the difficulty in substituting premarket requirements with postmarket conditions to speed approval decisions. At a recent Drug Information Association meeting, he recounted: "Recently we had a company approve a really high-profile product, and as one of the conditions of approval of that product, we said we need you to start a registry of new patients so we can see if some of the issues that came up in clinical trials premarket are understood in postmarket, and we're looking forward to it. Several months after the company marketed the product and had sold many, many thousands [of products]...a couple of adverse events showed up that we didn't understand. So we called the company, and we said, 'Hey, we're getting pressure. Clinicians are worried about this. We're worried about this. What have you got on the registry so we can help figure out whether this is a real safety problem?' And you know what they said? 'Registry? Oh, that was a condition of approval. We should have started that. Darn. We've sold thousands of the product, and you know, we haven't registered one person'"...

You may also be interested in...

Prenatal Vitamin D Benefit In Preventing Childhood Asthma Fades By Age 6

University of Rochester researchers say a benefit of daily prenatal vitamin D in preventing asthma in children up to 3 found in their 2016 study doesn't extend until age 6. They encourage more research, including analyzing whether supplementation should continue in young children.

UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System

At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.

Win For Axonics As England’s NICE Says Rechargeable Neuromodulation Is Cost-Effective

Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts